Advertisement

International Urogynecology Journal

, Volume 30, Issue 11, pp 1857–1862 | Cite as

Outcomes of intravesical chondroitin-sulfate and combined hyaluronic-acid/chondroitin-sulfate therapy on female sexual function in bladder pain syndrome

  • Burak ArslanEmail author
  • Serkan Gönültaş
  • Ersin Gökmen
  • Oktay Özman
  • Mustafa Asım Avci
  • Enver Özdemir
Original Article

Abstract

Introduction and hypothesis

Our aim was to determine the efficacy of intravesical chondroitin sulfate (CS) and combined hyaluronic acid/chondroitin sufate (HA/CS) treatment and their effects on sexual function of females with interstitial cystitis/bladder pain syndrome (IC/BPS).

Methods

A total of 68 female patients with IC/BPS between 2012 and 2018 were reviewed. Thirty-three patients were treated with combined HA/CS and 28 patients were treated with CS. Instillations were performed weekly for the first month, biweekly for the second month, and monthly in the third and fourth months. Before and after the sixth month of the treatment, all patients were evaluated with the Female Sexual Function Index (FSFI), visual analog pain scale (VAS), interstitial cystitis symptom index (ICSI), interstitial cystitis problem index (ICPI), and voiding diary, and changes were recorded.

Results

A statistically significant improvement was determined for FSFI, VAS, ICSI, and ICPI scores after treatment in both groups. Among baseline characteristics, a weak but significant negative correlation was determined only between the ICSI score improvement and age (rho: −0.38; p = 0.03) on statistical analysis. Compared with CS, combined HA/CS treatment was superior in terms of ICSI, ICPI, and daytime and nighttime frequency improvement (0.042, 0.038, 0.039, and 0.045; respectively). All domains of the sexual function index were significantly improved at the sixth month of intravesical therapy in both groups. A statistical difference was not found between the two groups.

Conclusions

Although it seems that intravesical HA/CS combination is superior to CS alone in terms of symptom reduction, both of them have beneficial effects on sexual function.

Keywords

Interstitial cystitis Sexual function Chondroitin sulfate Hyaluronic acid 

Notes

Compliance with ethical standards

Conflicts of interest

None.

References

  1. 1.
    Bogart LM, Berry SH, Clemens JQ. Symptoms of interstitial cystitis, painful bladder syndrome, and similar diseases in women: a systematic review. J Urol. 2007;177(2):450–6.CrossRefGoogle Scholar
  2. 2.
    van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.CrossRefGoogle Scholar
  3. 3.
    Meng E, Hsu YC, Chuang YC. Advances in intravesical therapy for bladder pain syndrome (BPS)/interstitial cystitis (IC). Low Urin Tract Symptoms. 2018;10(1):3–11.CrossRefGoogle Scholar
  4. 4.
    Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–4.CrossRefGoogle Scholar
  5. 5.
    Suskind AM, Berry SH, Ewing BA, Elliott MN, Suttorp MJ, Clemens JQ. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND interstitial cystitis epidemiology male study. J Urol. 2013;189(1):141–5.CrossRefGoogle Scholar
  6. 6.
    Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel J, Proietti S, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61(1):29–53.CrossRefGoogle Scholar
  7. 7.
    Lazzeri M, Hurle R, Casale P, Buffi N, Lughezzani G, Fiorini G, et al. Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence. Ther Adv Urol. 2016;8(2):91–9.CrossRefGoogle Scholar
  8. 8.
    Arslan B, Onuk O, Eroglu A, Gezmis CT, Aydin M. Female sexual function following a novel transobturator sling procedure without paraurethral dissection (modified-TOT). Int Braz J Urol. 2017;43(1):142–9.CrossRefGoogle Scholar
  9. 9.
    Gardella B, Porru D, Ferdeghini F, Martinotti E, Nappi RE, Rovereto B, et al. Insight into urogynecologic features of women with interstitial cystitis/painful bladder syndrome. Eur Urol. 2008;54(5):1145–53.CrossRefGoogle Scholar
  10. 10.
    Engeler D, Baranowski AP, Borovicka J, Cottrell AM, Dinis-Oliveira P, Elneil S, et al. EAU guidelines on chronic pelvic pain. In: European Association of Urology guideline. Arnhem, The Netherlands; 2018. p. 1–82.Google Scholar
  11. 11.
    Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.CrossRefGoogle Scholar
  12. 12.
    Sirinian E, Azevedo K, Payne CK. Correlation between 2 interstitial cystitis symptom instruments. J Urol. 2005;173(3):835–40.CrossRefGoogle Scholar
  13. 13.
    Hurst RE, Roy JB, Min KW, Veltri RW, Marley G, Patton K, et al. A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis. Urology. 1996;48(5):817–21.CrossRefGoogle Scholar
  14. 14.
    Parsons CL, Lilly JD, Stein P. Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol. 1991;145(4):732–5.CrossRefGoogle Scholar
  15. 15.
    Droupy S, Goddard JC. Intravesical glycosaminoglycan therapy—overall conclusions. Urologia. 2017;84(Suppl 1):21.CrossRefGoogle Scholar
  16. 16.
    Steinhoff G, Ittah B, Rowan S. The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol. 2002;9(1):1454–8.PubMedGoogle Scholar
  17. 17.
    Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L, et al. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int. 2009;103(1):56–60.CrossRefGoogle Scholar
  18. 18.
    Gulpinar O, Esen B, Kayıs A, Gokce MI, Suer E. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate in the treatment of bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2018;37(1):257–62.CrossRefGoogle Scholar
  19. 19.
    Porru D, Leva F, Parmigiani A, Barletta D, Choussos D, Gardella B, et al. Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. Int Urogynecol J. 2012;23(9):1193–9.CrossRefGoogle Scholar
  20. 20.
    Pyo JS, Cho WJ. Systematic review and meta-analysis of intravesical hyaluronic acid and hyaluronic acid/chondroitin sulfate instillation for interstitial cystitis/painful bladder syndrome. Cell Physiol Biochem. 2016;39(4):1618–25.CrossRefGoogle Scholar
  21. 21.
    Cervign M, Natale F, Nasta L, Mako A. Intravesical hyaluronic acid and chondroitin sulphate for bladder pain syndrome/interstitial cystitis: long-term treatment results. Int Urogynecol J. 2012;23(9):1187–92.CrossRefGoogle Scholar
  22. 22.
    Gardella B, Porru D, Nappi RE, Dacco MD, Chiesa A, Spinillo A. Interstitial cystitis is associated with vulvodynia and sexual dysfunction—a case control study. J Sex Med. 2011;8(6):1726–34.CrossRefGoogle Scholar
  23. 23.
    Ottem DP, Carr LK, Perks AE, Lee P, Teichman JM. Interstitial cystitis and female sexual dysfunction. Urology. 2007;69(4):608–10.CrossRefGoogle Scholar
  24. 24.
    Hung MJ, Su TH, Lin YH, Huang WC, LiN TY, Hsu CS, et al. Changes in sexual function of women with refractory intertitial cystitis/bladder pain syndrome after intravesical therapy with a hyaluronic acid solution. J Sex Med. 2014;11(9):2256–63.CrossRefGoogle Scholar
  25. 25.
    Nickel JC, Parsons CL, Forrest J, Kaufman D, Evans R, Chen A, et al. Improvement in sexual functioning in patients with interstitial cystitis/painful bladder syndrome. J Sex Med. 2008;5(2):394–9.CrossRefGoogle Scholar
  26. 26.
    Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1–20.CrossRefGoogle Scholar

Copyright information

© The International Urogynecological Association 2019

Authors and Affiliations

  1. 1.Department of UrologyIstanbul Gaziosmanpasa Taksim Training and Research HospitalIstanbulTurkey

Personalised recommendations